




RealRate

# MEDICINAL PRODUCTS 2023

## Celldex Therapeutics Inc. Rank 14 of 48





RealRate

# MEDICINAL PRODUCTS 2023

## Celldex Therapeutics Inc. Rank 14 of 48



The relative strengths and weaknesses of Celldex Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celldex Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 120% points. The greatest weakness of Celldex Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 92% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	317,693
Assets, Non-Current	4,105
General and Administrative Expense	27,195
Goodwill	27,190
Liabilities, Current	18,610
Liabilities, Non-Current	7,921
Other Assets	0
Other Compr. Net Income	-634
Other Expenses	8,138
Other Liabilities	0
Other Net Income	0
Other Revenues	5,266
Property, Plant and Equipment, Net	3,747
Research and Development	82,258

Output Variable	Value in 1000 USD
Liabilities	26,531
Assets	352,735
Expenses	117,591
Revenues	5,266
Stockholders Equity	326,204
Net Income	-112,325
Comprehensive Net Income	-112,642
Economic Capital Ratio	87%